Cerus Corporation (CERS)’s Financial Results Comparing With Reata Pharmaceuticals Inc. (NASDAQ:RETA)

Both Cerus Corporation (NASDAQ:CERS) and Reata Pharmaceuticals Inc. (NASDAQ:RETA) are Biotechnology companies, competing one another. We will contrast their dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cerus Corporation 60.62M 14.35 52.84M -0.42 0.00
Reata Pharmaceuticals Inc. 53.96M 47.45 71.64M -2.64 0.00

Demonstrates Cerus Corporation and Reata Pharmaceuticals Inc. earnings per share (EPS), gross revenue and valuation.

Profitability

Table 2 demonstrates the return on equity, net margins and return on assets of Cerus Corporation and Reata Pharmaceuticals Inc.

Net Margins Return on Equity Return on Assets
Cerus Corporation -87.17% -68.9% -38%
Reata Pharmaceuticals Inc. -132.77% 68.2% -34.6%

Liquidity

Cerus Corporation’s Current Ratio is 3.5 while its Quick Ratio is 3.2. On the competitive side is, Reata Pharmaceuticals Inc. which has a 6 Current Ratio and a 6 Quick Ratio. Reata Pharmaceuticals Inc. is better positioned to pay off short and long-term obligations compared to Cerus Corporation.

Insider & Institutional Ownership

Cerus Corporation and Reata Pharmaceuticals Inc. has shares owned by institutional investors as follows: 63.3% and 68%. Insiders owned 1.6% of Cerus Corporation shares. Competitively, 3.9% are Reata Pharmaceuticals Inc.’s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Cerus Corporation 4.95% -6.61% -22.72% -16.39% 50.96% 63.02%
Reata Pharmaceuticals Inc. -5.68% -16.44% -28.5% 59.68% 127.24% 110.31%

For the past year Cerus Corporation has weaker performance than Reata Pharmaceuticals Inc.

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System is based on its proprietary technology for controlling biological replication; and targets and inactivates blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products. The companyÂ’s INTERCEPT Blood Systems for platelets and plasma are designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion. It markets platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was founded in 1991 and is headquartered in Concord, California.

Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on identifying, developing, and commercializing product candidates for patients with rare and life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. Its lead product candidates include Bardoxolone methyl, which is in Phase III clinical trial for the treatment of pulmonary arterial hypertension and associated with connective tissue disease, as well as in Phase II clinical trial for the treatment of pulmonary hypertension due to interstitial lung disease and pulmonary arterial hypertension; and Omaveloxolone that is in Phase II clinical trial for the treatment of FriedreichÂ’s ataxia, mitochondrial myopathies, and metastatic melanoma. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. The company was founded in 2002 and is headquartered in Irving, Texas.